Abstract
The treatment of tumors has been a wide concern by a large number of scientific researchers. Combining magnetic resonance imaging (MRI) with photothermal therapy (PTT) enables cancer theranostics to be more efficient and accurate. Herein, we synthesized CuS@BSA nanoparticles with an average grain diameter of about 16.5 nm through a facile one-pot eco-friendly and user-friendly strategy and it was found to have strong near-infrared absorption property and magnetic resonance imaging ability so that it can be utilized as a multifunctional agent for cancer theranostic. The in vitro toxicity study showed that CuS@BSA nanoparticles with low toxicity could kill cancer cells with the 980 nm NIR laser effectively. Furthermore, they exhibit a certain value of relaxivity (r1 = 0.26 mM-1·s-1) compared to that of clinically widely used reagent Magnevist (r1 = 3.13 mM-1·s-1). The resulting product of CuS@BSA nanoparticles with their magnetic resonance imaging (MRI) and photothermal therapeutic capabilities could represent a kind of potential candidate for cancer theranostics.
| Original language | English |
|---|---|
| Pages (from-to) | 2332-2340 |
| Number of pages | 9 |
| Journal | ACS Applied Nano Materials |
| Volume | 1 |
| Issue number | 5 |
| DOIs | |
| State | Published - 25 May 2018 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 13 Climate Action
Keywords
- CuS@BSA nanoparticles
- MRI contrast agent
- low cytotoxicity
- photothermal therapy (PTT)
- theranostics
Fingerprint
Dive into the research topics of 'Combining Magnetic Resonance Imaging with Photothermal Therapy of CuS@BSA Nanoparticles for Cancer Theranostics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver